{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:24:12Z","timestamp":1788942252022,"version":"build-2803163510"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T00:00:00Z","timestamp":1473638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0162758","type":"journal-article","created":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T17:34:22Z","timestamp":1473701662000},"page":"e0162758","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["PDGF-BB Promotes Type I IFN-Dependent Vascular Alterations and Monocyte Recruitment in a Model of Dermal Fibrosis"],"prefix":"10.1371","volume":"11","author":[{"given":"John S.","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry C.","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor L.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Sofia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hamann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda C.","family":"Burkly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,9,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-pathol-011110-130312","article-title":"The pathogenesis of systemic sclerosis","volume":"6","author":"TR Katsumoto","year":"2011","journal-title":"Annual review of pathology"},{"issue":"7","key":"ref2","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"LM Rice","year":"2015","journal-title":"The Journal of clinical investigation"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1371\/journal.pone.0001452","article-title":"Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?","volume":"3","author":"JN Fleming","year":"2008","journal-title":"PloS one"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/1523-1747.ep12276895","article-title":"Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma","volume":"92","author":"S Gay","year":"1989","journal-title":"The Journal of investigative dermatology"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/01.RES.0000134644.89917.96","article-title":"Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis","volume":"95","author":"O Distler","year":"2004","journal-title":"Circulation research"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1101\/gad.1653708","article-title":"Role of platelet-derived growth factors in physiology and medicine","volume":"22","author":"J Andrae","year":"2008","journal-title":"Genes & development"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/art.1780331011","article-title":"Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis","volume":"33","author":"L Klareskog","year":"1990","journal-title":"Arthritis and rheumatism"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/1529-0131(199905)42:5<930::AID-ANR11>3.0.CO;2-1","article-title":"Activation of microvascular pericytes in autoimmune Raynaud&apos;s phenomenon and systemic sclerosis","volume":"42","author":"VS Rajkumar","year":"1999","journal-title":"Arthritis and rheumatism"},{"issue":"25","key":"ref9","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis","volume":"354","author":"SS Baroni","year":"2006","journal-title":"The New England journal of medicine"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1038\/jid.2010.200","article-title":"Poly(I:C) drives type I IFN- and TGFbeta-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis","volume":"130","author":"GA Farina","year":"2010","journal-title":"The Journal of investigative dermatology"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/art.22382","article-title":"A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists","volume":"56","author":"MR York","year":"2007","journal-title":"Arthritis and rheumatism"},{"issue":"7","key":"ref12","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/ard.2009.121400","article-title":"Type I interferon system activation and association with disease manifestations in systemic sclerosis","volume":"69","author":"ML Eloranta","year":"2010","journal-title":"Annals of the rheumatic diseases"},{"issue":"5","key":"ref13","first-page":"625","article-title":"Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis","volume":"22","author":"R Solans","year":"2004","journal-title":"Clinical and experimental rheumatology"},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2169\/internalmedicine.46.6328","article-title":"Systemic sclerosis after interferon alphacon-1 therapy for hepatitis C","volume":"46","author":"H Tahara","year":"2007","journal-title":"Internal medicine"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1312625","article-title":"Activated STING in a vascular and pulmonary syndrome","volume":"371","author":"Y Liu","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"8","key":"ref16","first-page":"1202","article-title":"Macrophage infiltration in the skin of patients with systemic sclerosis","volume":"19","author":"O Ishikawa","year":"1992","journal-title":"The Journal of rheumatology"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.devcel.2011.04.019","article-title":"PDGFRbeta signaling regulates mural cell plasticity and inhibits fat development","volume":"20","author":"LE Olson","year":"2011","journal-title":"Developmental cell"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1172\/JCI40891","article-title":"IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice","volume":"120","author":"JS Cho","year":"2010","journal-title":"The Journal of clinical investigation"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.4049\/jimmunol.174.10.5936","article-title":"Cutting edge: re-evaluating the in vivo cytokine responses of CD8+ T cells during primary and secondary viral infections","volume":"174","author":"F Liu","year":"2005","journal-title":"Journal of immunology"},{"issue":"Suppl 5","key":"ref20","doi-asserted-by":"crossref","first-page":"v2","DOI":"10.1093\/rheumatology\/ken265","article-title":"Role of PDGF in fibrotic diseases and systemic sclerosis","volume":"47","author":"M Trojanowska","year":"2008","journal-title":"Rheumatology"},{"issue":"12","key":"ref21","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1136\/annrheumdis-2013-203729","article-title":"Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors","volume":"72","author":"B Maurer","year":"2013","journal-title":"Annals of the rheumatic diseases"},{"key":"ref22","first-page":"266","article-title":"The role of type 1 interferon in systemic sclerosis","volume":"4","author":"M Wu","year":"2013","journal-title":"Frontiers in immunology"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1136\/annrheumdis-2013-203535","article-title":"Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis","volume":"73","author":"B Maurer","year":"2014","journal-title":"Annals of the rheumatic diseases"},{"issue":"8","key":"ref24","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/emboj\/21.8.1939","article-title":"Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy","volume":"21","author":"Y Dor","year":"2002","journal-title":"The EMBO journal"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s004010051071","article-title":"Aicardi-Goutieres syndrome: a genetic microangiopathy?","volume":"98","author":"PG Barth","year":"1999","journal-title":"Acta neuropathologica"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4292\/wjgpt.v2.i1.6","article-title":"Digital ischemic necrosis caused by pegylated interferon in a patient with hepatitis C","volume":"2","author":"JG Hashash","year":"2011","journal-title":"World journal of gastrointestinal pharmacology and therapeutics"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.4049\/jimmunol.1300376","article-title":"A synthetic TLR3 ligand mitigates profibrotic fibroblast responses by inducing autocrine IFN signaling","volume":"191","author":"F Fang","year":"2013","journal-title":"Journal of immunology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13075-015-0721-3","article-title":"Nilotinib (Tasigna) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial","volume":"17","author":"JK Gordon","year":"2015","journal-title":"Arthritis research & therapy"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1046\/j.1523-1747.1999.00528.x","article-title":"Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma","volume":"112","author":"T Yamamoto","year":"1999","journal-title":"The Journal of investigative dermatology"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1002\/art.27647","article-title":"Animal models of systemic sclerosis: prospects and limitations","volume":"62","author":"C Beyer","year":"2010","journal-title":"Arthritis and rheumatism"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0162758","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T11:39:00Z","timestamp":1589024340000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0162758"}},"subtitle":[],"editor":[{"given":"Shervin","family":"Assassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,9,12]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,9,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0162758","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,12]]}}}